Francesca Pica

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6175992/publications.pdf

Version: 2024-02-01

55 papers	1,401 citations	257357 24 h-index	360920 35 g-index
55 all docs	55 docs citations	55 times ranked	1762 citing authors

#	Article	IF	Citations
1	A Systematic Analysis of Host Factors Reveals a Med23-Interferon-Î» Regulatory Axis against Herpes Simplex Virus Type 1 Replication. PLoS Pathogens, 2013, 9, e1003514.	2.1	88
2	Transmission of human herpesvirus 8: an update. Current Opinion in Infectious Diseases, 2007, 20, 152-156.	1.3	74
3	Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives. World Journal of Gastrointestinal Oncology, 2016, 8, 30.	0.8	67
4	Clinical and psychosocial correlates of postâ€herpetic neuralgia. Journal of Medical Virology, 2008, 80, 1646-1652.	2.5	65
5	Thymosin Î±1 and cancer: action on immune effector and tumor target cells. Annals of the New York Academy of Sciences, 2012, 1269, 26-33.	1.8	62
6	HERVs Expression in Autism Spectrum Disorders. PLoS ONE, 2012, 7, e48831.	1.1	55
7	Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. International Immunopharmacology, 2005, 5, 1205-1212.	1.7	54
8	Combination treatment using thymosin Î±1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunology, Immunotherapy, 1990, 32, 154-160.	2.0	53
9	Combination therapy with thymosin Î±1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice. International Journal of Cancer, 1992, 50, 493-499.	2.3	48
10	Transcriptional Activity of Human Endogenous Retroviruses in Human Peripheral Blood Mononuclear Cells. BioMed Research International, 2015, 2015, 1-9.	0.9	46
11	Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopharmacology, 2000, 22, 1067-1076.	1.1	44
12	Thymosin Alpha 1. Annals of the New York Academy of Sciences, 2007, 1112, 225-234.	1.8	41
13	In vivo cocaine administration influences lymphokine production and humoral immune response. Immunologic Research, 1992, 11, 74-79.	1.3	39
14	Thymosin Î±1 in combination with cytokines and chemotherapy for the treatment of cancer. International Immunopharmacology, 2003, 3, 1145-1150.	1.7	37
15	Increased levels of p70S6 phosphorylation in the G93A mouse model of Amyotrophic Lateral Sclerosis and in valine-exposed cortical neurons in culture. Experimental Neurology, 2010, 226, 218-230.	2.0	37
16	Antitumor Effect of Thymosin Î±1/Interleukin-2 or Thymosin Î±1/Interferon Î±,Î² Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia Cells. Journal of Immunotherapy, 1993, 13, 7-17.	1.2	36
17	Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer. Anti-Cancer Drugs, 2012, 23, 32-42.	0.7	36
18	Î” ¹² -Prostaglandin J ₂ Is a Potent Inhibitor of Influenza A Virus Replication. Antimicrobial Agents and Chemotherapy, 2000, 44, 200-204.	1.4	31

#	Article	IF	Citations
19	Thymosin Î±1 as a stimulatory agent of innate cellâ€mediated immune response. Annals of the New York Academy of Sciences, 2012, 1270, 13-20.	1.8	29
20	Thymosin Î±₁ Activates Complement Receptor-Mediated Phagocytosis in Human Monocyte-Derived Macrophages. Journal of Innate Immunity, 2014, 6, 72-88.	1.8	29
21	Historical review on thymosin Î±1 in oncology: preclinical and clinical experiences. Expert Opinion on Biological Therapy, 2015, 15, 31-39.	1.4	28
22	Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clinical and Experimental Research, 2018, 30, 693-702.	1.4	28
23	Antifungal activity of Cardiospermum halicacabum L. (Sapindaceae) against Trichophyton rubrum occurs through molecular interaction with fungal Hsp90. Drug Design, Development and Therapy, 2018, Volume 12, 2185-2193.	2.0	27
24	Clinical and psychosocial correlates of acute pain in herpes zoster. Journal of Clinical Virology, 2007, 38, 275-279.	1.6	25
25	High expression of Endogenous Retroviruses from intrauterine life to adulthood in two mouse models of Autism Spectrum Disorders. Scientific Reports, 2018, 8, 629.	1.6	24
26	Thymosin-Î±1 expands deficient IL-10-producing regulatory B cell subsets in relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 127-139.	1.4	23
27	Human Herpesvirus 8 DNA in Serum During Seroconversion in Allogeneic Bone Marrow Transplant Recipients. Journal of the National Cancer Institute, 2005, 97, 1008-1011.	3.0	21
28	Cytomegalovirus infection in day care centers in Rome, Italy: Viral excretion in children and occupational risk among workers. Journal of Medical Virology, 1988, 26, 119-125.	2.5	20
29	Thymosin Î±1 Interacts with Exposed Phosphatidylserine in Membrane Models and in Cells and Uses Serum Albumin as a Carrier. Biochemistry, 2016, 55, 1462-1472.	1.2	20
30	Thymosin alpha one restores murine T-cell-mediated responses inhibited by In vivo cocaine administration. International Journal of Immunopharmacology, 1992, 14, 1-9.	1.1	16
31	Thymosin Î±1 inserts N terminus into model membranes assuming a helical conformation. Expert Opinion on Biological Therapy, 2015, 15, 71-81.	1.4	16
32	Taking Screenshots of the Invisible: A Study on Bacterial Contamination of Mobile Phones from University Students of Healthcare Professions in Rome, Italy. Microorganisms, 2020, 8, 1075.	1.6	16
33	Neutralizing Antibody Response against Human Cytomegalovirus in Allogeneic Bone Marrowâ€“Transplant Recipients. Journal of Infectious Diseases, 1999, 180, 1747-1748.	1.9	14
34	Autocrine nerve growth factor is essential for cell survival and viral maturation in HHV-8â€“infected primary effusion lymphoma cells. Blood, 2000, 95, 2905-2912.	0.6	13
35	Interferon-Î» in immunocompetent individuals with a history of recurrent herpes labialis. Antiviral Therapy, 2010, 15, 737-743.	0.6	13
36	New studies about the insertion mechanism of Thymosin Î±1 in negative regions of model membranes as starting point of the bioactivity. Amino Acids, 2016, 48, 1231-1239.	1.2	13

#	Article	IF	Citations
37	One-year follow-up of patients with long-lasting post-herpetic neuralgia. BMC Infectious Diseases, 2014, 14, 556.	1.3	12
38	Serum thymosin alpha 1 levels in normal and pathological conditions. Expert Opinion on Biological Therapy, 2018, 18, 13-21.	1.4	12
39	Frequency of Herpes Zoster Recurrence. Mayo Clinic Proceedings, 2011, 86, 586.	1.4	11
40	Deciphering cellular biological processes to clinical application: a new perspective for TÎ±1 treatment targeting multiple diseases. Expert Opinion on Biological Therapy, 2018, 18, 23-31.	1.4	11
41	Public awareness and knowledge of herpes labialis. Journal of Medical Virology, 2012, 84, 132-137.	2.5	10
42	Viruses of Respiratory Tract: an Observational Retrospective Study on Hospitalized Patients in Rome, Italy. Microorganisms, 2020, 8, 501.	1.6	10
43	Thymosin Î±1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK. Molecules, 2017, 22, 1843.	1.7	9
44	Combination therapy with BRMs in cancer and infectious diseases. Mechanisms of Ageing and Development, 1997, 96, 103-116.	2.2	6
45	Antiviral treatment of varicella in pediatric practice in the Latium region of Italy: results of an observational study. Pediatric Infectious Disease Journal, 2002, 21, 739-742.	1.1	5
46	Microbial contamination of the surface of mobile phones and implications for the containment of the Covid-19 pandemic. Travel Medicine and Infectious Disease, 2020, 37, 101870.	1.5	5
47	Potential mechanism of thymosin-Î±1-membrane interactions leading to pleiotropy: experimental evidence and hypotheses. Expert Opinion on Biological Therapy, 2018, 18, 33-42.	1.4	4
48	Rationale for Therapeutic Approaches with Thymosin Î± 1, Interleukin 2 and Interferon in Combination with Chemotherapy. , 1992, , 275-281.		4
49	Cidofovir on Hhv-8 in Bcbl-1 Cells. Antiviral Therapy, 2004, 9, 823-825.	0.6	4
50	Effect of extremely low frequency electromagnetic fields (ELF-EMF) on Kaposi's sarcoma-associated herpes virus in BCBL-1 cells. Bioelectromagnetics, 2006, 27, 226-232.	0.9	3
51	Combination Therapy with Thymosin Î±1 and Cytokines in the Treatment of Cancer and Infectious Diseases. , 1993, , 49-60.		3
52	Cidofovir on HHV-8 in BCBL-1 cells. Antiviral Therapy, 2004, 9, 823-5.	0.6	2
53	Thymosin Î±1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK. Molecules, 2017, 22, 1843.	1.7	1
54	Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. New Microbiologica, 2017, 40, 107-112.	0.1	1

#	Article	IF	Citations
55	Efficacy of the Combined Treatment with Fluconazole and Thymosin Î± 1 Against Candida albicans Infection in Morphine-Treated Mice. , 1993, , 189-194.		0